Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Dr. Tabernero on New Characterizations in CRC

October 18th 2013

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Impact of Molecular Testing on First-Line Treatment Decisions in NSCLC

October 18th 2013

Five lung cancer experts discuss recent advances and current issues surrounding the treatment of non-small cell lung cancer

Expanding TKI Therapy in Advanced Lung Cancer

October 9th 2013

Amid rapid progress in the treatment of advanced lung cancer, several leading organizations have joined in developing new guidelines for the optimal use of molecular testing to help select patients for therapy with tyrosine kinase inhibitors

Dr. Camidge on AP26113 in Advanced Malignancies

October 7th 2013

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

Dr. Carbone on Potential Biomarkers in Lung Cancer

October 3rd 2013

David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.

Dr. Hudis on BOLERO-3 Trial Biomarker Observations

October 1st 2013

Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, attending physician, Memorial Sloan-Kettering Cancer Center, comments on exploratory biomarker observations from the BOLERO-3 trial.

Dr. Markman on Targets for the Treatment of Ovarian Cancer

September 30th 2013

Maurie Markman, MD, from the Cancer Treatment Centers of America, discusses the discovery of mutations and targets in ovarian cancer and the current progress being made in the development of a "breakthrough" agent for ovarian cancer.

Personalized Medicine in Colorectal Cancer

September 29th 2013

Novel Therapies in Development for mCRC

September 29th 2013

Second-Line and Salvage Treatment of mCRC

September 29th 2013

Antiangiogenic Therapy in Metastatic Colorectal Cancer

September 29th 2013

Maintenance Therapy in Metastatic Colorectal Cancer

September 29th 2013

Case Study: Borderline Resectable mCRC

September 29th 2013

Predictive Value of RAS Mutations in mCRC

September 29th 2013

FIRE-3 Study: Cetuximab Versus Bevacizumab in mCRC

September 29th 2013

EPOC Studies: Preoperative Treatments in CRC

September 29th 2013

PRIME Trial: RAS Mutations in Metastatic Colorectal Cancer

September 29th 2013

TRIBE Trial: First-Line Treatment of mCRC

September 29th 2013